CO6230981A2 - Formas solidas de (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahidroxibutil)-1h-imidazol-2-il)etanona oxima - Google Patents

Formas solidas de (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahidroxibutil)-1h-imidazol-2-il)etanona oxima

Info

Publication number
CO6230981A2
CO6230981A2 CO09112459A CO09112459A CO6230981A2 CO 6230981 A2 CO6230981 A2 CO 6230981A2 CO 09112459 A CO09112459 A CO 09112459A CO 09112459 A CO09112459 A CO 09112459A CO 6230981 A2 CO6230981 A2 CO 6230981A2
Authority
CO
Colombia
Prior art keywords
imidazol
tetrahydroxybutyl
solid form
hydrate
ethanone
Prior art date
Application number
CO09112459A
Other languages
English (en)
Inventor
Wenxue Wu
Haiming Zhang
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of CO6230981A2 publication Critical patent/CO6230981A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Una forma sólida sustancialmente amorfa de (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahidroxibutil)-1H-imidazol-2-il)-etanona oxima o su hidrato.2.- La forma sólida de la reivindicación 1, en dondeel (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahidroxibutil)-1Himidazol-2-il)-etanona oxima es anhidra.3.- La forma sólida de la reivindicación 1, en dondeel hidrato es un monohidrato.4.- La forma sólida de la reivindicación 1, en dondeel hidrato es un dihidrato.5.- Una forma sólida sustancialmente cristalina de(E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahidroxibutil)-1H-imidazol-2-il)- etanona oxima o su hidrato.6.- La forma sólida de la reivindicación 5, en dondeel (E)1-(4-((1R,2S,3R)-1,2,3,4-tetrahidroxibutil)-1Himidazol-2-il)-etanona oxima es anhidra.7.- La forma sólida de la reivindicación 5, en dondeel hidrato es un monohidrato.8.- La forma sólida de la reivindicación 5, en dondeel hidrato es un dihidrato.9.- (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahidroxibutil)-1Himidazol-2-il)-etanona oxima cristalina anhidra.10.- El (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahidroxibutil)-1H-imidazol-2-il)-etanona oxima cristalino anhidro de lareivindicación 9, que tiene un espectro de difracción depolvo de rayos X que comprende picos deaproximadamente 4.7, 8.2 y 12.5 grados 2Θ.11.- El (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahidroxibutil)-1H-imidazol-2-il)-etanona oxima cristalino anhidro de lareivindicación 9, que tiene un espectro de difracción depolvo de rayos X que comprende picos deaproximadamente 17.1, 19.9 y 20.8 grados 2Θ.12.- El (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahidroxibutil)-1H-imidazol-2-il)-etanona oxima cristalino anhidro de lareivindicación 9, que tiene un espectro de difracción depolvo de rayos X que comprende picos deaproximadamente 29.3, 32.0 y 33.1 grados 2Θ.
CO09112459A 2007-04-12 2009-10-09 Formas solidas de (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahidroxibutil)-1h-imidazol-2-il)etanona oxima CO6230981A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92303707P 2007-04-12 2007-04-12

Publications (1)

Publication Number Publication Date
CO6230981A2 true CO6230981A2 (es) 2010-12-20

Family

ID=39639233

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09112459A CO6230981A2 (es) 2007-04-12 2009-10-09 Formas solidas de (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahidroxibutil)-1h-imidazol-2-il)etanona oxima

Country Status (23)

Country Link
US (2) US20080275099A1 (es)
EP (1) EP2139865B1 (es)
JP (1) JP5496080B2 (es)
KR (1) KR20100015464A (es)
CN (1) CN101284818B (es)
AR (1) AR065979A1 (es)
AU (1) AU2008240255B2 (es)
BR (1) BRPI0810197A2 (es)
CA (1) CA2683963A1 (es)
CL (1) CL2008001043A1 (es)
CO (1) CO6230981A2 (es)
EA (1) EA017042B1 (es)
EC (1) ECSP099681A (es)
ES (1) ES2453543T3 (es)
HK (1) HK1124851A1 (es)
IL (1) IL201037A (es)
MX (1) MX2009010904A (es)
NZ (1) NZ579689A (es)
PE (1) PE20090072A1 (es)
TW (1) TWI412362B (es)
UY (1) UY31012A1 (es)
WO (1) WO2008128045A1 (es)
ZA (1) ZA200906493B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
TW200848029A (en) 2007-03-01 2008-12-16 Lexicon Pharmaceuticals Inc Heterocyclic compounds, compositions comprising them and methods of their use
AR065980A1 (es) * 2007-04-12 2009-07-15 Lexicon Pharmaceuticals Inc Metodos para preparar compuestos basados en imidazol
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
JP5550644B2 (ja) * 2008-06-18 2014-07-16 レクシコン ファーマシューティカルズ インコーポレイテッド （１ｒ，２ｓ，３ｒ）−１−（２−（イソオキサゾール−３−イル）−１ｈ−イミダゾール−４−イル）ブタン−１，２，３，４−テトラオールの固体形態及びその使用方法
US8653126B2 (en) 2010-02-18 2014-02-18 Daiichi Sankyo Company, Limited Imidazole derivative
JP5757635B2 (ja) 2010-06-28 2015-07-29 第一三共株式会社 培養細胞を用いたｓ１ｐリアーゼ阻害剤のスクリーニング方法
TW201311710A (zh) 2011-06-28 2013-03-16 Daiichi Sankyo Co Ltd 磷酸酯衍生物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567194A (en) * 1983-03-10 1986-01-28 The Coca-Cola Company 2-Acylimidazole compounds, their synthesis and use as medicinal agents
ZA974811B (en) * 1996-05-31 1997-12-30 Univ Wollongong Novel therapeutic compounds.
CN101395141A (zh) * 2006-02-24 2009-03-25 莱西肯医药有限公司 咪唑基化合物，包含其的组合物和它们的使用方法
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
AR065980A1 (es) * 2007-04-12 2009-07-15 Lexicon Pharmaceuticals Inc Metodos para preparar compuestos basados en imidazol

Also Published As

Publication number Publication date
AR065979A1 (es) 2009-07-15
AU2008240255A1 (en) 2008-10-23
HK1124851A1 (es) 2009-07-24
JP2010523707A (ja) 2010-07-15
US20090298901A1 (en) 2009-12-03
IL201037A0 (en) 2010-05-17
TW200848027A (en) 2008-12-16
EP2139865B1 (en) 2014-01-01
WO2008128045A8 (en) 2010-01-21
BRPI0810197A2 (pt) 2014-12-30
TWI412362B (zh) 2013-10-21
WO2008128045A1 (en) 2008-10-23
UY31012A1 (es) 2008-09-02
ES2453543T3 (es) 2014-04-08
CA2683963A1 (en) 2008-10-23
ECSP099681A (es) 2009-12-28
CN101284818B (zh) 2012-10-03
EP2139865A1 (en) 2010-01-06
NZ579689A (en) 2011-10-28
JP5496080B2 (ja) 2014-05-21
EA200970940A1 (ru) 2010-02-26
MX2009010904A (es) 2009-10-26
US8658682B2 (en) 2014-02-25
ZA200906493B (en) 2010-11-24
AU2008240255B2 (en) 2013-07-04
KR20100015464A (ko) 2010-02-12
IL201037A (en) 2015-08-31
US20080275099A1 (en) 2008-11-06
CN101284818A (zh) 2008-10-15
EA017042B1 (ru) 2012-09-28
PE20090072A1 (es) 2009-02-18
CL2008001043A1 (es) 2008-09-26

Similar Documents

Publication Publication Date Title
CO6230981A2 (es) Formas solidas de (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahidroxibutil)-1h-imidazol-2-il)etanona oxima
LTC2404919I2 (lt) Heterociklinis junginys, tinkamas panaudoti kaip ATP-rišančių kasečių transporterių moduliatorius
ES2488165T3 (es) Hidrocloruro de nalmefeno dihidrato
NO20081930L (no) Oksazolforbindelser og farmasoytiske blandinger
ZA200802636B (en) Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds as inhibitors of the beta-secretase (BACE)
IL192024A0 (en) 3,5-substituted piperidine compounds as renin inhibitors
TW200715632A (en) Inorganic compounds
WO2007103839A3 (en) Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
PL1896426T3 (pl) Sposób syntezy związków organicznych
EA201000395A1 (ru) Фунгицидные производные 2-алкилтио-2-хинолинилоксиацетамида
DE602006013342D1 (de) Druck-verriegelung
WO2007002313A3 (en) Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
CL2008000795A1 (es) Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil)piperazina para el tratamiento del dolor o de los sintomas residuales de la depresion; y dicho compuesto.
GB0521508D0 (en) Organic compounds
CL2007002034A1 (es) Compuestos derivados de hidroximoil-tetrazol; composicion fungicida que comprende dichos compuestos uso del compuesto o la composicion para controlar de forma curativa o preventiva los hongos fitopatogenos de las plantas o cultivos;y metodo para controlar hongos pitopatogenos de plantas o cultivos.
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
BRPI0811103A2 (pt) Compostos triazol para tratamento de formação de biopelícula
AR059715A1 (es) Variedades cristalinas de pesticidas derivados de 2-metil-4-trifluorometiltiazol-5-il
HK1117502A1 (en) Mono-lysine salts of azole compounds
ECSP088374A (es) Formulacion de aerosol para inhalacion
GT200600427A (es) Compuestos organicos
GT200600102A (es) Procedimiento para la preparacion de compuestos benzoxazol sustituidos
ES2489467T3 (es) Polimorfo novedoso del clorhidrato del éster (6-dimetilaminometil-2-naftalenílico) del ácido (4-hidroxicarbamoilfenil)-carbámico
ZA200709621B (en) Process for the synthesis of organic compounds
ITTO20060264A1 (it) Procedimento di fabbricazione di una struttura di memoria non volatile mediante litografia "soffice"

Legal Events

Date Code Title Description
FC Application refused